FTC and DOJ Target Healthcare and Life Sciences Industries

FTC and DOJ Target Healthcare and Life Sciences Industries

Client Alert

Related Documents

Related Solutions

We offer clients exceptional insight in dealing with competition agencies in the United States, Europe and around the world.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Guiding clients through high-stakes and sensitive investigations.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

The healthcare industry remains a focal point of President Biden’s antitrust agenda. The President’s July 2021 Executive Order on Promoting Competition in the American Economy called on federal agencies to focus antitrust enforcement efforts on health care, among other industries, and to coordinate on oversight, investigations, and remedies where agency jurisdiction overlaps. The Federal Trade Commission (FTC), the Department of Justice Antitrust Division (DOJ), and the Department of Health and Human Services (HHS) later announced plans to address antitrust concerns in the healthcare industry. FTC Chair Lina M. Khan highlighted ongoing healthcare-related enforcement initiatives in a February 2024 speech before the American Medical Association. The FTC, DOJ, and HHS launched an interagency inquiry into private equity and corporate ownership in health care shortly thereafter. In this client alert, we summarize the latest federal antitrust activities in the healthcare industry.

Read the full alert.

Authors

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel